Distinct DNA methylation patterns associated with treatment resistance in metastatic castration resistant prostate cancer
Abstract Androgens are a major driver of prostate cancer (PCa) and continue to be a critical treatment target for advanced disease, which includes castration therapy and antiandrogens. However, resistance to these therapies leading to metastatic castration-resistant prostate cancer (mCRPC), and the...
Enregistré dans:
Auteurs principaux: | Madonna R. Peter, Misha Bilenky, Alastair Davies, Ruth Isserlin, Gary D. Bader, Neil E. Fleshner, Martin Hirst, Amina Zoubeidi, Bharati Bapat |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Nature Portfolio
2021
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/8a0d4c3f1dab4fb8aab66b888d10d9ef |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Cabazitaxel in the treatment of metastatic castration-resistant prostate cancer
par: Nikolai A. Ognerubov
Publié: (2021) -
Integrating evolutionary dynamics into treatment of metastatic castrate-resistant prostate cancer
par: Jingsong Zhang, et autres
Publié: (2017) -
Advanced Therapeutic Options for Treatment of Metastatic Castration Resistant Prostatic Adenocarcinoma
par: Faiza Naseer, et autres
Publié: (2021) -
Clinical characteristics and outcomes for patients with non‑metastatic castration-resistant prostate cancer
par: Peter Arnold, et autres
Publié: (2021) -
Metastatic castration-resistant prostate cancer in very elderly patients: challenges and solutions
par: Caffo O, et autres
Publié: (2016)